UNITED
      STATES


SECURITIES
      AND
      EXCHANGE COMMISSION


Washington,
      D.C.
      20549




**FORM
      6-K**




**REPORT
      OF
      FOREIGN PRIVATE ISSUER**





**Pursuant
      to
      Rule 13a-16 or 15d-16**


**Under
      the
      Securities Exchange Act of 1934**




For
      the month
      of June 2006




Commission
      File
      Number: 0-29350




**Vasogen
      Inc.**


(Translation
      of
      registrant’s name into English)




**2505
      Meadowvale Blvd, Mississauga, Ontario, L5N 5S2**


(Address
      of
      principal executive offices)




Indicate
      by check mark whether the registrant files or will file annual reports under
      cover of Form 20-F or Form 40-F.




Form
                20-Fo
            
            Form
                40-Fý







Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1).  o




Note:
      Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form
      6-K
      if submitted solely to provide an attached annual report to security holders.




Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):  o




Note:
      Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form
      6-K
      if submitted to furnish a report or other document that the registrant foreign
      private issuer must furnish and make public under the laws of the jurisdiction
      in which the registrant is incorporated, domiciled or legally organized (the
      registrant's "home country"), or under the rules of the home country exchange
      on
      which the registrant's securities are traded, as long as the report or other
      document is not a press release, is not required to be and has not been
      distributed to the registrant's security holders, and, if discussing a material
      event, has already been the subject of a Form 6-K submission or other Commission
      filing on EDGAR.




Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.




Yeso
            
            Noý





If
“Yes”
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-  .







On
                        June
                        29, 2006, Vasogen Inc. issued a press release “Vasogen’s ACCLAIM Results to be
                        Presented at the Heart Failure Society of America Meeting
                        in
                        September.”
 
 The
                        press
                        release is attached as Exhibit 99.1 to this report and is
                        incorporated herein by
                        reference.


**SIGNATURE**





Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned, thereunto
      duly authorized.








VASOGEN
                  INC.By:
              /s/
                  Jacqueline H.R. Le SauxName:
              Jacqueline
                  H.R. Le SauxTitle:
              Vice-President,
                  Corporate & Legal
                  Affairs





Date:
      June 29, 2006





**EXHIBIT
      LIST**





Exhibit
            Description99.1
            Press
                        release of Vasogen Inc. dated June 29,
                        2006